INC Research Demonstrates Ongoing Commitment to Clinical Research Sites at SCRS 2016 Global Site Solutions Summit

RALEIGH, N.C., Oct. 12, 2016 (GLOBE NEWSWIRE) — INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced its extensive participation in the Society for Clinical Research Sites’ (SCRS) 11th Annual Global Site Solutions Summit Oct. 13-16 in Boca Raton, Fla. INC Research thought leaders will participate in seven sessions to discuss issues that impact the way sites conduct research and recruit patients, while offering strategies to improve collaboration between CROs and sites to more effectively benefit patients.

INC Research will commence its participation with Clare Grace, PhD, Vice President, Site and Patient Access, participating in the summit’s first plenary session, “Sites Matter: Industry Collaboration,” which will explore ongoing transformations affecting sites, including investigator turnover, general public awareness of clinical research, site study dashboards, site payments and standardized contract clauses. On Day 2 of the summit, Dr. Grace will facilitate a Site Solving™ Break-Out Session around solving the clinical trial awareness challenge and share notable highlights from the recent “Inspiring Hope” Ideathon, a crowdsolving event that INC Research and the Center for Information and Study on Clinical Research Participation (CISCRP) co-hosted last month in Boston, which brought together a cross-section of stakeholders across the industry to share and develop innovative ideas for increasing awareness of and participation in clinical trials.

“We are excited to once again be participating in the SCRS Global Site Solutions Summit — an event that consistently has been instrumental in bringing sites, CROs and sponsors together to improve how we all work together in clinical research,” said Clare Grace, PhD, Vice President, Site and Patient Access. “The strides we’ve made in recent years to streamline different aspects of the clinical trial process, such as investigator payments, is evidence of this collaboration, but we still have a long way to go. Connecting with sites in such a synergistic environment gives us an opportunity to gain a better understanding of their perspectives and remain mindful of all of the valuable contributions they make in bringing new medicines to market. Without sites, we simply wouldn’t be able to deliver clinical trials.”